These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33426467)

  • 1. An overview of the use of biomaterials, nanotechnology, and stem cells for detection and treatment of COVID-19: towards a framework to address future global pandemics.
    Ghaffari M; Mollazadeh-Bajestani M; Moztarzadeh F; Uludağ H; Hardy JG; Mozafari M
    Emergent Mater; 2021; 4(1):19-34. PubMed ID: 33426467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies.
    Hasanzadeh A; Alamdaran M; Ahmadi S; Nourizadeh H; Bagherzadeh MA; Mofazzal Jahromi MA; Simon P; Karimi M; Hamblin MR
    J Control Release; 2021 Aug; 336():354-374. PubMed ID: 34175366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.
    Weiss C; Carriere M; Fusco L; Capua I; Regla-Nava JA; Pasquali M; Scott JA; Vitale F; Unal MA; Mattevi C; Bedognetti D; Merkoçi A; Tasciotti E; Yilmazer A; Gogotsi Y; Stellacci F; Delogu LG
    ACS Nano; 2020 Jun; 14(6):6383-6406. PubMed ID: 32519842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnology-based Approaches and Investigational Therapeutics against COVID-19.
    Rahman MM; Ahmed M; Islam MT; Khan MR; Sultana S; Maeesa SK; Hasan S; Hossain MA; Ferdous KS; Mathew B; Rauf A; Uddin MS
    Curr Pharm Des; 2022; 28(12):948-968. PubMed ID: 34218774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?
    Sportelli MC; Izzi M; Kukushkina EA; Hossain SI; Picca RA; Ditaranto N; Cioffi N
    Nanomaterials (Basel); 2020 Apr; 10(4):. PubMed ID: 32326343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobiosensors for the Detection of Novel Coronavirus 2019-nCoV and Other Pandemic/Epidemic Respiratory Viruses: A Review.
    Alhalaili B; Popescu IN; Kamoun O; Alzubi F; Alawadhia S; Vidu R
    Sensors (Basel); 2020 Nov; 20(22):. PubMed ID: 33218097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects.
    Varahachalam SP; Lahooti B; Chamaneh M; Bagchi S; Chhibber T; Morris K; Bolanos JF; Kim NY; Kaushik A
    Int J Nanomedicine; 2021; 16():539-560. PubMed ID: 33519200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology-based theranostic and prophylactic approaches against SARS-CoV-2.
    Dhar A; Gupta SL; Saini P; Sinha K; Khandelwal A; Tyagi R; Singh A; Sharma P; Jaiswal RK
    Immunol Res; 2024 Feb; 72(1):14-33. PubMed ID: 37682455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnology-based strategies against SARS-CoV-2 variants.
    Huang X; Kon E; Han X; Zhang X; Kong N; Mitchell MJ; Peer D; Tao W
    Nat Nanotechnol; 2022 Oct; 17(10):1027-1037. PubMed ID: 35982317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomedical application, drug delivery and metabolic pathway of antiviral nanotherapeutics for combating viral pandemic: A review.
    Mukherjee S; Mazumder P; Joshi M; Joshi C; Dalvi SV; Kumar M
    Environ Res; 2020 Dec; 191():110119. PubMed ID: 32846177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis.
    Zhang X; Guo M; Huang Z; Huang Y; Wu C; Pan X
    Infect Med (Beijing); 2022 Jun; 1(2):103-112. PubMed ID: 38013718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities for biomaterials to address the challenges of COVID-19.
    Chakhalian D; Shultz RB; Miles CE; Kohn J
    J Biomed Mater Res A; 2020 Oct; 108(10):1974-1990. PubMed ID: 32662571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2.
    Mufamadi MS; Ngoepe MP; Nobela O; Maluleke N; Phorah B; Methula B; Maseko T; Masebe DI; Mufhandu HT; Katata-Seru LM
    Biomed Res Int; 2023; 2023():4588659. PubMed ID: 37181817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients.
    Hashemi B; Akram FA; Amirazad H; Dadashpour M; Sheervalilou M; Nasrabadi D; Ahmadi M; Sheervalilou R; Ameri Shah Reza M; Ghazi F; Roshangar L
    J Drug Deliv Sci Technol; 2022 Jan; 67():102967. PubMed ID: 34777586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can nanotechnology help to combat COVID-19? Opportunities and urgent need.
    Campos EVR; Pereira AES; de Oliveira JL; Carvalho LB; Guilger-Casagrande M; de Lima R; Fraceto LF
    J Nanobiotechnology; 2020 Sep; 18(1):125. PubMed ID: 32891146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotechnology-Based Strategies for the Management of COVID-19: Recent Developments and Challenges.
    Singh R; Behera M; Kumari N; Kumar S; Rajput VD; Minkina TM; Adnan M; Siddiqui AJ; Kumar N
    Curr Pharm Des; 2021; 27(41):4197-4211. PubMed ID: 34459371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Applications of separation technology in novel coronavirus research, epidemic prevention and detection].
    Li L; Zhu C; Zhao X; Qu F
    Se Pu; 2021 Jul; 39(7):679-685. PubMed ID: 34227364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.
    Bchetnia M; Girard C; Duchaine C; Laprise C
    J Infect Public Health; 2020 Nov; 13(11):1601-1610. PubMed ID: 32778421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.